**Supplemental Digital Content 2**

Change in efficacy endpoints from baseline (Part B of the TRAVERS trial)

|  | **Placebo** | **AM-125 10 mg** | **AM-125 20 mg** |
| --- | --- | --- | --- |
|  | **N=32** | **N=34** | **N=33** |
| **Tandem Romberg test, sec.**  |  |  |  |
| Δ Day 7 | 3.418 (1.169; 5.668) | 2.119 (-0.113; 4.351) | 3.411 (1.190; 5.632) |
| Δ Day 14 | 5.198 (2.919; 7.477) | 6.362 (4.127; 8.598) | 7.070 (4.794; 9.347) |
| Δ Day 28 | 7.415 (5.110; 9.721) | 8.191 (5.929; 10.454) | 10.876 (8.548; 13.205) |
| Δ Day 42 | 10.714 (8.435; 12.993) | 10.519 (8.283; 12.754) | 11.202 (8.928; 13.476) |
| **Standing on Foam test, sec.**  |  |  |  |
| Δ Day 7 | 13.552 (10.553; 16.550) | 9.499 (6.558;12.439) | 11.778 (8.790; 14.766) |
| Δ Day 14 | 14.778 (11.746; 17.811) | 15.898 (12.953;18.843) | 18.467 (15.410; 21.524) |
| Δ Day 28 | 21.537 (18.482; 24.593) | 18.762 (15.788; 21.735) | 19.138 (15.985; 22.291) |
| Δ Day 42 | 22.391 (19.359; 25.424) | 22.242 (19.297; 25.187) | 23.403 (20.355; 26.451) |
| **Spontaneous nystagmus, beats/30 sec.**  |  |  |  |
| Δ Day 7 | -10.013 (15.149; -4.878) | -5.217 (-10.292; -0.143) | -6.495 (-11.554; -1.436) |
| Δ Day 14 | -15.879 (-21.075; -10.682) | -23.235 (-28.321; -18.149) | -20.482 (-25.600; -15.364) |
| Δ Day 28 | -27.998 (-33.254; -22.742) | -27.168 (-32.313; -22.022) | -27.044 (-32.341; -21.748) |
| Δ Day 42 | -27.266 (-32.462; -22.069) | -32.078 (-37.164; -26.992) | -30.428 (-35.604; -25.252) |
| **Tandem Gait test, steps**  |  |  |  |
| Δ Day 7 | 8.141 (6.494; 9.789) | 6.759 (5.133; 8.384) | 9.676 (8.036; 11.317) |
| Δ Day 14 | 13.991 (12.326; 15.656) | 13.005 (11.374; 14.636) | 13.546 (11.874; 15.218) |
| Δ Day 28 | 17.002 (15.323; 18.681) | 14.596 (12.949; 16.242) | 14.429 (12.727; 16.130) |
| Δ Day 42 | 16.862 (15.197; 18.527) | 15.224 (13.593; 16.855) | 16.171 (14.501; 17.842) |
| **Subjective visual vertical, degrees** |  |  |  |
| Δ Day 7 | -1.595 (-2.275; -0.916) | -1.474 (-2.141; -0.808) | -1.695 (-2.364; -1.027) |
| Δ Day 14 | -3.273 (-3.954; -2.592) | -3.127 (-3.794; -2.459) | -3.109 (-3.791; -2.428) |
| Δ Day 28 | -4.340 (-5.027; -3.653) | -4.496 (-5.170; -3.822) | -3.957 (-4.658; -3.256) |
| Δ Day 42 | -4.612 (-5.292; -3.931) | -4.761 (-5.429; -4.093) | -4.353 (-5.034; -3.672) |
| **Vestibular Rehabilitation Benefit Questionnaire** |  |  |  |
| Δ Day 7 | -15.151 (-19.997; -10.305) | -14.685 (-19.673; -9.697) | -18.679 (-23.613; -13.745) |
| Δ Day 14 | -22.558 (-27.457; -17.659) | -20.848 (-25.784; -15.913) | -26.334 (-31.325; -21.343) |
| Δ Day 28 | -27.558 (-32.503; -22.614) | -22.648 (-27.584; -17.713) | -28.756 (-33.852; -23.660) |
| Δ Day 42 | -30.095 (-34.994; -25.197) | -28.232 (-33.167; -23.296)  | -32.892 (-37.935; -27.849) |

Improvement from baseline (Day 3 post surgery). Mixed-effects model with repeated measures using baseline values and age as covariates; least square means with 90% confidence interval, no adjustment for multiplicity. “Intention-to-treat” analysis set.